ACRO's CRO Forum Will Liaise with TransCelerate
The Association of Clinical Research Organizations held its inaugural meeting of the CRO Forum. The Forum was established in October 2014 as the primary vehicle for interaction between the CRO industry and TransCelerate BioPharma.
The Association of Clinical Research Organizations held its inaugural meeting of the CRO Forum. The Forum was established in October 2014 as the primary vehicle for interaction between the CRO industry and TransCelerate BioPharma. ACRO and TransCelerate have mutually agreed to initially establish liaison relationships between four TransCelerate workstreams: risk-based monitoring; shared site qualification and training; common protocol template; and quality management system.
The Forum elected as its first Chairman Dr. Alan Metz, Senior Vice President and Managing Director, Strategic Partnerships, at Quintiles. As Vice Chair, the Forum elected Amy Kissam, Executive Director, Global Operational Management, at INC Research. In addition, the CRO Forum selected senior subject matter experts to serve as liaisons to each of the workstreams, and will be supported by working groups consisting of subject matter experts from across the Forum membership.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
